<DOC>
	<DOC>NCT03099330</DOC>
	<brief_summary>To study the pharmacokinetic characteristics of TQ-B3139 in the human body, recommend a reasonable regimen for subsequent research.</brief_summary>
	<brief_title>A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics</brief_title>
	<detailed_description />
	<criteria>Histological documentation of Advanced solid tumors Lack of the standard treatment or treatment failure 1865years,ECOG PS:01,Life expectancy of more than 3 months Patients with antitreatment or surgery within 4 weeks Main organs function is normal Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be nonlactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped Patients should participate in the study voluntarily and sign informed consent Patients participated in other anticancer drug clinical trials within 4 weeks Blood pressure unable to be controlled(systolic pressure&gt;140 mmHg，diastolic pressure&gt;90 mmHg). Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥470ms) Patients with nonhealing wounds or fractures Patients with drug abuse history and unable to get rid of or Patients with mental disorders History of immunodeficiency Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>